论文部分内容阅读
目的观察社区获得性肺炎(CAP)早期有效抗生素的选择。方法 2012年10月-2014年10月住院的CAP患者60例,按照不同病情分为治疗组35例和对照组25例,治疗组给予莫西沙星注射液0.4g静脉滴注,每天1次。对照组给予注射用头孢哌酮钠/舒巴坦钠按2~6g/d,12h 1次联合注射阿奇霉素0.5g,每天1次,静脉滴注,疗程均为7~10d。结果治疗组总有效率为85.7%明显高于对照组的64.0%(P<0.01),不良事件发生率及与药物相关的不良反应发生率均低于对照组,差异均有统计学意义(P<0.05)。结论莫西沙星在治疗CAP中安全、有效、不良反应发生率低。
Objective To observe the selection of effective early antibiotics in community-acquired pneumonia (CAP). Methods From October 2012 to October 2014, 60 CAP patients admitted to hospital were divided into treatment group (35 cases) and control group (25 cases). The treatment group was given moxifloxacin 0.4g intravenously once daily. The control group was given cefoperazone sodium / sulbactam sodium for injection by 2 ~ 6g / d, 12h once combined azithromycin 0.5g, 1 day, intravenous infusion, the course of treatment is 7 ~ 10d. Results The total effective rate was 85.7% in the treatment group, which was significantly higher than that in the control group (64.0%, P <0.01). The incidence of adverse events and drug-related adverse reactions were both lower than those in the control group (P <0.05). Conclusion Moxifloxacin is safe and effective in the treatment of CAP with a low incidence of adverse reactions.